Crossmark

Analysis and prediction of the efficacy and influencing factors of camrelizumab combined with TACE and sorafenib in the treatment of advanced hepatocellular carcinoma

Crossref DOI link: https://doi.org/10.1007/s00432-023-05050-0

Published Online: 2023-07-14

Published Print: 2023-10

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Pan, Songsong

Zheng, Jiaxi

Shi, Changsheng
Funding

Funding for this research was provided by:

Zhejiang Provincial Medicine and Health Science and Technology Program (2020KY297)
License Information

Text and Data Mining valid from 2023-07-14

Version of Record valid from 2023-07-14
More Information

Article History

Received: 14 May 2023

Accepted: 28 June 2023

First Online: 14 July 2023

Declarations

:

: All authors have no conflicts of interest to disclose.

: This study is a retrospective study. The basic information of patients is not involved in the study. The ethics committees of Taizhou Hospital and Ruian People's Hospital allow ethical reviews to be skipped.

: Informed consent was obtained from all individual participants included in the study.

: All authors consent to publish this article.

Document is current

Any future updates will be listed below